DNP-BSA
Based on 1 Customer Validation
DNP-BSA is a multivalent antigen and protein-binding reagent. DNP-BSA binds to subdomain IIA (Site I) of bovine serum albumin via predominantly hydrophobic forces, with spontaneous complex formation via combined dynamic and static quenching. DNP-BSA induces cross-linking of IgE-bound FceRI, triggering tyrosine phosphorylation of FceRI β and γ subunits. DNP-BSA binds to anti-DNP IgE via its DNP groups, forming cross-links between IgE-FceRI complexes, with most DNP groups initially unavailable but transiently exposed for binding. DNP-BSA induces FITC fluorescence quenching in FITC-labeled anti-DNP IgE, proportional to occupied IgE Fab binding sites. DNP-BSA can be used for the research of allergy, inflammation, and contact sensitivity (allergic contact dermatitis).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 95.00%
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
DNP-BSA forms spontaneously under physiological pH, with hydrophobic forces as the dominant driving force, as evidenced by positive ΔH° (46.22 kJ mol-1) and ΔS° (237.2 J mol-1 K-1) values and negative ΔG° values ranging from -24.46 to -29.21 kJ mol-1[1].
DNP-BSA forms at site I of BSA's subdomain IIA, forming stable interactions with Trp213, Leu197, Arg217, Asp450, and Leu480, with a docking score of -8.71 kcal/mol[1].
Stimulates FceRI β subunit tyrosine phosphorylation in RBL-2H3 cells that correlates directly with the kinetics of DNP-BSA-mediated IgE-FceRI cross-linking at 15°C, but shows a biphasic decline while cross-linking increases at 35°C[2].
DNP-BSA potently stimulates degranulation of adherent RBL-2H3 cells, inducing ~50% β-hexosaminidase release at concentrations of 0.2 nM and 1.1 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
DNP-BSA (100 µg per animal; epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days) suppresses DNFB-induced contact sensitivity and induces TCRab+ CD4+ CD25+ FoxP3+ regulatory T cells in C57BL/6 mice[3].
DNP-BSA (100 µg per animal; epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days) induces regulatory lymph node cells that potently suppress DNFB-induced contact sensitivity in B10.PL and related knockout mice, with suppression efficacy ranging from 80-92%[3].
DNP-BSA (100 µg per animal; epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days) induces regulatory T cells that distribute equally across peripheral lymphoid tissues and suppress DNFB-induced contact sensitivity in NOD mice[3].
DNP-BSA (100 µg per animal; epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days) suppresses DNFB-induced lymph node cell proliferation by 43-56% and reduces proinflammatory cytokine production in BALB/c mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (H-2d) (female, 6-10 weeks of age)[3]
-
Dosage:100 µg per animal; 3 µg per animal
-
Administration:epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days
-
Result:Reduced DNFB-induced ear swelling to 26% of the positive control, vascular permeability to 19% of the positive control, ear weight to 46% of the positive control, myeloperoxidase activity to 50% of the positive control, and IFN-γ concentration in ear extracts to 50% of the positive control.
Significantly inhibited ear swelling (3 µg dose).
Increased the absolute number of TCRab+ CD4+ CD25+ FoxP3+ regulatory T cells in auxiliary and inguinal lymph nodes compared to PBS-treated mice.
Reduced ear swelling to 50% of the positive control when 5×107 lymph node cells from DNP-BSA-patched mice were transferred 2 hours before DNFB sensitization.
Reduced ear swelling to 56% of the positive control when 5×107 lymph node cells from DNP-BSA-patched mice were transferred 2 hours before challenge.
Reduced ear swelling to 40% of the positive control at 24 hours and 28% at 48 hours when 5×107 lymph node cells from DNP-BSA-patched mice were transferred 4 hours after DNFB challenge.
Reduced ear swelling to 38% of the positive control when administered 1 day after DNFB sensitization.
Reduced ear swelling after rechallenge to 13% of the positive control when administered 1 day after the first DNFB challenge.
-
Animal Model:C57BL/6 (H-2b) (female, 6-10 weeks of age)[3]
-
Dosage:100 µg per animal
-
Administration:epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days
-
Result:Significantly suppressed DNFB-induced ear swelling compared to PBS-treated mice.
Increased the absolute number of TCRab+ CD4+ CD25+ FoxP3+ regulatory T cells in auxiliary and inguinal lymph nodes.
-
Animal Model:B10.PL (H-2u), β2m-/-, TCRδ-/-, CD1d-/- (6-10 weeks of age)[3]
-
Dosage:100 µg per animal
-
Administration:epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days
-
Result:Reduced DNFB-induced ear swelling to 32% of the positive control when lymph node cells from DNP-BSA-patched B10.PL mice were transferred.
Reduced DNFB-induced ear swelling to 13% of the positive control when lymph node cells from DNP-BSA-patched β2m-/- mice were transferred.
Reduced DNFB-induced ear swelling to 20% of the positive control when lymph node cells from DNP-BSA-patched TCRδ-/- mice were transferred.
Reduced DNFB-induced ear swelling to 8% of the positive control when lymph node cells from DNP-BSA-patched CD1d-/- mice were transferred.
-
Animal Model:NOD, FoxP3-FIR NOD (6-10 weeks of age)[3]
-
Dosage:100 µg per animal
-
Administration:epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days
-
Result:Resulted in a higher percentage of FoxP3+ regulatory T cells in auricular lymph nodes, auxiliary/inguinal lymph nodes, and spleens of DNFB-sensitized recipients compared to recipients receiving cells from PBS-treated donors.
-
Animal Model:BALB/c (H-2d) (female, 6-10 weeks of age)[3]
-
Dosage:100 µg per animal
-
Administration:epicutaneous, via occlusive patch; days 0 and 4, each patch left in place for 3 days
-
Result:Reduced lymph node cell proliferation (measured by [3H]-thymidine uptake) to 44-57% of the positive control across DNP-BSA concentrations of 30, 100, and 300 µg/mL.
Reduced production of IL-12 to ~57% of the positive control, TNF-α to ~68% of the positive control, and IFN-γ to ~64% of the positive control in lymph node cell cultures.
化学情報
-
性状 Liquid
-
Color Light yellow to yellow
-
SMILES
[DNP-BSA]
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
TPA/Croton Oil Ear Edema and Dermatitis
The TPA (12-O-tetradecanoylphorbol-13-acetate) and croton oil-induced mouse ear edema model is a well-established acute cutaneous inflammation system used to evaluate topical anti-inflammatory activity by measuring edema formation, neutrophil infiltration, vascular permeability, and cytokine-mediated skin responses in vivo. The inflammatory response is triggered by topical application of phorbol esters (TPA) or croton oil constituents, leading to rapid activation of protein kinase C signaling, leukocyte recruitment, and increased vascular permeability, which can be quantified by ear thickness, weight, dye extravasation, and biochemical markers such as myeloperoxidase (MPO) activity and pro-inflammatory mediators in ear tissue homogenates. This model is widely used for screening anti-inflammatory agents, where reductions in edema and inflammatory biomarkers reflect suppression of acute dermal inflammation and immune cell infiltration. Histological evaluation typically confirms epidermal
-
Contact Hypersensitivity Dermatitis
Contact hypersensitivity (CHS) dermatitis is a T cell-mediated delayed-type (Type IV) immune reaction in which low-molecular-weight haptens applied to the skin bind host proteins to form complete antigens, triggering sensitization followed by a secondary inflammatory response upon re-exposure (elicitation phase), which is commonly quantified by ear swelling as a readout of skin inflammation in murine models. This model is widely used to study allergic contact dermatitis because it is antigen-specific, reproducible, and reflects key immunological events including dendritic cell activation, T cell priming in draining lymph nodes, and effector T cell-driven tissue inflammation. DNFB- and oxazolone-induced CHS models are standard systems for evaluating both acute and chronic T cell-dependent skin inflammation and for testing immunomodulatory interventions.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. El Gammal RN, et al. Insights on the in-vitro binding interaction between donepezil and bovine serum albumin. BMC chemistry. 2023 Apr 06;17(1):31. [Content Brief]
[2]. Xu K, et al. Kinetics of multivalent antigen DNP-BSA binding to IgE-Fc epsilon RI in relationship to the stimulated tyrosine phosphorylation of Fc epsilon RI. J Immunol. 1998 Apr 1;160(7):3225-35. [Content Brief]
[3]. Majewska-Szczepanik M, et al. Epicutaneous immunization with DNP-BSA induces CD4+ CD25+ Treg cells that inhibit Tc1-mediated CS. Immunology and cell biology. 2012 Sep;90(8):784-95. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)